Literature DB >> 8142680

Adult Still's disease with Sjögren's syndrome successfully treated with intravenous pulse methylprednisolone and oral cyclophosphamide.

M Sato1, A Takeda, H Honzu, N Saku, N Minato, S Kano.   

Abstract

A patient with adult Still's disease and Sjögren's syndrome failed to respond to conventional doses of corticosteroids. Therefore intravenous pulse methylprednisolone combined with oral cyclophosphamide was given which subsequently resolved the flare of rashes, fevers, and arthritis. This combination therapy may be a useful therapy to consider in patients with adult Still's disease who are resistant to conventional treatment and may allow a reduction in daily corticosteroid requirement.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8142680     DOI: 10.2169/internalmedicine.32.730

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.

Authors:  Alexander Kokkinos; Alexios Iliopoulos; Paraskevi Greka; Anna Efthymiou; Nicholas Katsilambros; Petros P Sfikakis
Journal:  Clin Rheumatol       Date:  2003-11-15       Impact factor: 2.980

Review 2.  Sjögren's syndrome with adult-onset Still's disease: an overlap syndrome?

Authors:  Pingyang Han; Chen Sun; Yinghong Zhang; Juzhen Yan
Journal:  Rheumatol Int       Date:  2021-05-20       Impact factor: 2.631

3.  Adult onset Still's disease in the elderly: a case-based literature review.

Authors:  Arash Mollaeian; Jingjing Chen; Nina N Chan; Gregory A Nizialek; Christopher J Haas
Journal:  BMC Rheumatol       Date:  2021-04-20

4.  Case Report: A Rare Case of Elderly-Onset Adult-Onset Still's Disease in a Patient With Systemic Lupus Erythematosus.

Authors:  Yasuaki Hirooka; Saki Okuda; Masafumi Sugiyama; Toshihiko Shiga; Yuji Nozaki; Koji Kinoshita; Masanori Funauchi; Itaru Matsumura
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.